Drugs / IL-1Ra
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03383276 | Dec 2017 → Mar 2018 | keratoconjunctivitis | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00915590 | Apr 2009 → Mar 2011 | corneal neovascularization | Reza Dana, MD | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03249207 Comparator | Oct 2018 → Apr 2024 | acquired aneurysmal subarachnoid hemorrhage | University of Manchester | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Genascence Corporation | Results Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress genascence.com ↗
The study findings also showed that a single intra-articular injection of GNSC resulted in elevated interleukin-1 receptor antagonist (IL-1Ra) expression over baseline in synovial fluid for the length of the 12-month study. |
| 2022-05-17 | Genascence Corporation | Results Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting genascence.com ↗
Additional safety data, including 12-month follow-up on all subjects, demonstrated GNSC-001 is safe and well tolerated |
| 2022-05-05 | Genascence Corporation | Results Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis genascence.com ↗
Interim safety data results show that GNSC-001 was safe and well tolerated, with adverse events being absent (8/9) or mild/moderate (1/9) in all treated subjects. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-1Ra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383276 ↗ |
| Known as | Interleukin-1-Receptor Antagonist | “The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.” NCT00915590 ↗2“The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers.” NCT03383276 ↗ “Does Interleukin-1 Receptor Antagonist Improve Outcome Following Aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III Trial” NCT03249207 ↗ |
| Action | Inhibit | “Topical Interleukin-1-Receptor Antagonist” NCT03383276 ↗ |
| Route | Topical | “5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks” NCT00915590 ↗ |